AbbVie Ventures is focused on early-stage opportunities in oncology, immunology, neuroscience, eye care, and aesthetics.
Accent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.
ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.
Artios Pharma is developing cancer treatments that target DNA Damage Response pathways to selectively kill cancer cells.
Capsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.
Carisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.
DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.
Disc Medicine is developing therapies addressing ineffective red blood cell production in hematologic diseases.
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.
Faze Medicines is pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.
FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.
Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology.
PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.
Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Quanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.
Ribon Therapeutics is discovering first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress.
Stemson Therapeutics is developing a novel treatment for hair loss, using iPS cells to grow new Dermal Papilla and generate hair follicles de novo.
Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.
Chemoproteomics Stealth NewCo is developing activity-dependent protein ligation technology for quantitative in-cell profiling.
IPO, NASDAQ: ALEC
Acquired by Gilead
Acquired by CSL Behring
IPO, NASDAQ: CRBU
Merger with Aduro Biotech, NASDAQ: KDNY
Acquired by Lilly
Acquired by Locust Walk Acquisition Corp (SPAC merger), NASDAQ: EFTR
IPO, NASDAQ: XCUR
IPO, NASDAQ: KALA
Acquired by Zymergen
IPO, NASDAQ: MORF
Acquired by Lilly
Acquired by Amgen
Acquired by Sanofi
Acquired by Gilead
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?